Compare Abeona Therapeutics Inc (ABEO) vs MakeMyTrip Ltd (MMYT) Price & Performance
Price performance
Price movement over the last 24 hours
Key statistics
Key statistics
Abeona Therapeutics Inc vs MakeMyTrip Ltd — how do they compare? Abeona Therapeutics Inc trades at $6.74 (market cap $373.32M), while MakeMyTrip Ltd trades at $56.17 (market cap $5.57B). The key difference: MakeMyTrip Ltd is far larger — about 14.9× Abeona Therapeutics Inc's market cap, and Abeona Therapeutics Inc is trading nearer its 52-week high, MakeMyTrip Ltd nearer its low. Which is the better fit depends on your goals.
| ABEO | MMYT | |
|---|---|---|
Market Cap | $373.32M | $5.57B |
Sector | Health | Technology |
52-Week High | $7.23 | $103.21 |
52-Week Low | $4.17 | $36.30 |
Enterprise Value | $228.22M | $6.21B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
ABEO trades at $6.31, down 1.41% today, with a bullish technical outlook supported by moving averages. The company reported Q1 2026 results with revenue growth and beat EPS expectations, while maintaining strong profitability margins. Recent news highlights expansion of treatment centers and new cell therapy licensing.
Outlook remains positive with analyst consensus favoring Buy ratings (66.67%), though high RSI indicates potential near-term overbought conditions. Key risks include negative operating cash flow and reliance on new treatment adoption. Upside depends on continued commercial execution and pipeline advancements.
MakeMyTrip (MMYT) trades at $57.35, down 1.58% today but showing strong technical momentum with bullish moving averages. The company demonstrates robust fundamentals with Q1 2026 EPS beating expectations at $0.25 versus $0.1654, continuing a trend of earnings outperformance. Revenue reached $978.34M in 2025 with healthy 73.77% gross margins, though valuation metrics appear elevated with a P/E of 159.17. Analyst sentiment remains strongly positive with 72.73% buy ratings.
The outlook remains favorable given consistent earnings beats and strong travel demand recovery, though high valuation multiples and rising debt-to-asset ratios from 12.13% to 80.57% projected for 2026 present significant risks. Temporary travel disruptions have pressured growth, but platform resilience across hotel and package segments supports the bullish case. Investors should weigh growth potential against valuation concerns and increasing leverage.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Abeona Therapeutics Inc
Abeona Therapeutics develops gene and cell therapies for rare diseases. Its lead product, ZEVASKYN, is an FDA-approved therapy for recessive dystrophic epidermolysis bullosa (RDEB), a severe and life-threatening genetic skin disorder.
Read more on ABEO →About MakeMyTrip Ltd
MakeMyTrip Ltd. is a leading online travel company in India, providing a comprehensive range of travel services and products, including air tickets, hotels, holiday packages, rail tickets, and bus tickets. The company operates its primary websites and mobile apps under the brands MakeMyTrip, Goibibo, and RedBus. MMYT serves as a key intermediary in India's fragmented travel market, leveraging its platform to offer convenience and competitive pricing to consumers and businesses.
Read more on MMYT →
